

## Anti-PTPRC/CD45 Antibody (Novartis patent anti-CD45)

### Introduction

Novartis patent anti-CD45 is a CHO-expressed humanized antibody targeting PTPRC/CD45.

### Product parameters

Alternative Names	Novartis patent anti-CD45
Target Accession	P08575
Target	PTPRC / CD45
CAS number	/
Molecular Weight	150 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human IL-18 His at 4 ug/mL can bind Anti-PTPRC/CD45 Antibody (Novartis patent anti-CD45), EC50=0.00604 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## ■ Note

1. This product is for scientific research use only.



**APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

